BIOGEN INC. cotiza a 228.90 USD y tiene una capitalización bursátil de $33.8B. En los últimos 12 meses ha facturado $9.9B con un margen de flujo de caja libre del 20.7%. Cotiza a 14.0 veces su flujo de caja libre (P/FCF) y a un PER de 24.6. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSO…
| Periodo | 2026-10 | 2026-07 | 2026-04 | 2026-02 |
|---|---|---|---|---|
| Real | — | $3.60 | $3.57 | $1.99 |
| Estimado | $2.02 | $2.03 | $2.89 | $1.62 |
| Sorpresa | — | +77.3% | +23.5% | +22.8% |
| Métrica | BIIB | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 75.7% | 57.0% | +18.6% |
| Operating Margin | — | -38.6% | — |
| Net Margin | 13.1% | -33.6% | +46.6% |
| FCF Margin | 20.7% | -13.9% | +34.6% |
| ROE | 7.1% | -40.4% | +47.5% |
| ROA | 4.4% | -32.0% | +36.4% |
| Current Ratio | 2.68 | 2.84 | -0.16 |
| Debt / Equity | 0.34 | 0.28 | +0.06 |